Immunocompromised patients with viral severe acute respiratory infection in intensive care: an Australia wide, retrospective, observational study
Main finding · In-hospital mortalityResult — go to the resultAdjusted odds ratio 1.93 95% CI 1.57–2.37Authors' conclusion
In this study, we found that immunocompromised patients accounted for approximately one-fifth of critically ill viral SARI patients and had nearly twice the odds of in-hospital mortality, when compared to those that were immunocompetent.
Study context
- Population
- Critically ill adults (age ≥ 18) with laboratory-confirmed viral severe acute respiratory infection (severe acute respiratory infections (SARI)) admitted to intensive care unit (ICU), Australia, June 2022 to August 2025
- Participants
- 4,703 adults · 46 ICUs
- Exposure
- Immunocompromised vs immunocompetent patients
- Immunocompromisedn = 908
- Outcome
- In-hospital mortality
Methodological detailsnation-wide, multicentre (46 ICUs), mixed-effects logistic regression, competing risks regression (Fine and Gray)
- Nation-wide
- Multicentre (46 ICUs)
- Mixed-effects logistic regression
- Competing risks regression (Fine and Gray)
Main finding
As reported in the abstract
Adjusted odds ratio
1.93
95% CI 1.57–2.37
By group
Immunocompromised vs Immunocompetent
aOR 1.93 (95% CI 1.57–2.37)
Observational data: associations, not effects.
Further findings
Antiviral treatment
Corticosteroid treatment
- Antiviral treatment: p < 0.01
- Corticosteroid treatment: p < 0.01
Original publication
Immunocompromised patients with viral severe acute respiratory infection in intensive care: an Australia wide, retrospective, observational study. Crit Care. Published 17 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →